Blog
RSS FeedPosted by Michael Wonder on 30 Aug 2024
Public Summary Documents – May 2024 PBAC meeting
30 August 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2024 PBAC ...
Posted by Michael Wonder on 30 Aug 2024
Agenda for the September 2024 PBAC intracycle meeting
30 August 2024 - The agenda for the September 2024 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 29 Aug 2024
Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- ...
Posted by Michael Wonder on 25 Aug 2024
Risankizumab for the treatment of patients with moderately to severely active ulcerative colitis
23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of ...
Posted by Michael Wonder on 25 Aug 2024
Recommendations made by the PBAC – July 2024
23 August 2024 - Recommendations made by the PBAC in July 2024 relating to the listing of medicines on the ...
Posted by Michael Wonder on 22 Aug 2024
ICER publishes final evidence report on treatment for anaemia in myelodysplastic syndrome
22 August 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate net health benefits for ...
Posted by Michael Wonder on 22 Aug 2024
Benefits of new Alzheimer’s treatment lecanemab are too small to justify the cost to the NHS
22 August 2024 - Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, ...
Posted by Michael Wonder on 21 Aug 2024
EMA publishes agenda for 19-22 August 2024 CHMP meeting
19 August 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 19 Aug 2024
Update from the PBAC (August 2024)
19 August 2024 - An update from the Deputy Chair of the PBAC. ...
Posted by Michael Wonder on 14 Aug 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids (final guidance)
14 August 2024 - NICE has published final evidence-based recommendations on the use of linzagolix choline (Yselty) for the treatment ...
Posted by Michael Wonder on 14 Aug 2024
Relugolix for the treatment of patients with hormone sensitive prostate cancer
14 August 2024 - NICE has published final evidence-based recommendations on the use of relugolix (Orgovyx) for the treatment of ...
Posted by Michael Wonder on 13 Aug 2024
SMC - August 2024 decisions
12 August 2024 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 12 Aug 2024
Changes in revenues associated with antimicrobial reimbursement reforms in Germany
10 August 2024 - Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and ...
Posted by Michael Wonder on 10 Aug 2024
Two new treatment options for incurable blood cancer assessed
9 August 2024 - We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, ...
Posted by Michael Wonder on 09 Aug 2024
Novo Nordisk upset as Dutch agency advises against insurance cover for Wegovy
17 July 2024 - Danish drug maker Novo Nordisk said on Wednesday it was disappointed with the recommendation to the ...